2017 Virtual Symposium: Advances in Insulin Therapy: Addressing Provider and Patient Safety Concerns

Intensive insulin regimens often cause a higher risk of hypoglycemia and weight gain, which can contribute to a greater cardiometabolic burden in patients with T2DM. Hypoglycemia has been linked to several adverse outcomes, including falls, depression, autonomic dysfunction, cardiovascular morbidity, and thus a poor prognosis. Given the growing elderly population, improving glycemic control while preventing hypoglycemia is a focus of T2DM management. This CME symposium will address the use of new insulin therapies and combination treatments that have been shown to reduce cardiometabolic and hypoglycemic risk while achieving glycemic control.

Insulin in the Treatment of Diabetes

Presenter: Anne L. Peters, MD

Optimizing Insulin Therapy and Applying Evidence in Clinical Practice

Presenter: Deborah J. Wexler, MD, MSc

Audience Q&A

Presenter: Anne L. Peters, MDDeborah J. Wexler, MD, MSc